In vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657, new rifamycin derivatives

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  1994-05-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1128/AAC.38.5.1118PMID 8067748PMCID PMC188160
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Synthesis and biological activity of 3'-hydroxy-5'-aminobenzoxazinorifamycin derivatives.

  1993cited by this paper
• Therapeutic efficacy of the benzoxazinorifamycin KRM-1648 against experimental Mycobacterium avium infection induced in rabbits

  1993cited by this paper
• In vitro antimicrobial activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex, determined by the radiometric method

  1993cited by this paper
• Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex infection induced in mice

  1992cited by this paper
• [In vivo activities of new rifamycin derivatives against mycobacteria].

  1991cited by this paper
• In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins

  1991cited by this paper
• [In vitro activities of new rifamycin derivatives against Mycobacterium tuberculosis and M. avium complex].

  1990cited by this paper
• Differences in ability of cell-wall antibiotics to suppress emergence of rifampicin resistance in Staphylococcus aureus.

  1985cited by this paper
• Combination antibiotic therapy of bacterial endocarditis.

  1980cited by this paper

• Challenges and Potential of Antibody–Drug Conjugates as Prospective Tuberculosis Therapeutics

  2025cites this paper
• Novel antibody-antibiotic conjugate using KRM-1657 as payload eliminates intracellular MRSA in vitro and in vivo.

  2024cites this paper
• Rifabutin versus rifampicin bactericidal and antibiofilm activities against clinical strains of Staphylococcus spp. isolated from bone and joint infections.

  2022cites this paper
• Rifabutin to the Rescue?

  2020cites this paper
• Antibiofilm and intraosteoblastic activities of rifamycins against Staphylococcus aureus: promising in vitro profile of rifabutin.

  2020cites this paper
• Inhibition of RNA Polymerase by Rifampicin and Rifamycin-Like Molecules

  2020cites this paper
• Rifabutin: where do we stand in 2016?

  2016cites this paper
• IN-SILICO AND REAL-TIME BIOASSAYS BASED SCREENING OF PHYTOMOLECULES AND THEIR DERIVATIVES FOR ACTIVITY AGAINST COMMON DRUG RESISTANT BACTERIAL PATHOGENS INFECTING HUMANS

  2014cites this paper
• In vitro determination of the CYP 3A4 activity in rat hepatic microsomes by liquid-phase extraction and HPLC-photodiode array detection.

  2012cites this paper
• Rifamycins--obstacles and opportunities.

  2010cites this paper
• Rifamycins e Obstacles and opportunities

  2010cites this paper
• A Randomized, Double-Blind Study Comparing Single-Dose Rifalazil With Single-Dose Azithromycin for the Empirical Treatment of Nongonococcal Urethritis in Men

  2007cites this paper
• In Vitro Activity of Novel Rifamycins against Rifamycin-Resistant Staphylococcus aureus

  2006cites this paper
• Rifalazil Pretreatment of Mammalian Cell Cultures Prevents Subsequent Chlamydia Infection

  2006cites this paper
• Efficacy of Novel Rifamycin Derivatives against Rifamycin-Sensitive and -Resistant Staphylococcus aureus Isolates in Murine Models of Infection

  2006cites this paper
• Development potential of rifalazil and other benzoxazinorifamycins

  2006cites this paper
• In Vitro Time-kill Activities of Rifalazil, Alone and in Combination with Vancomycin, against Logarithmic and Stationary Cultures of Staphylococcus aureus

  2006cites this paper
• Enhanced Activity of Rifalazil in Combination with Levofloxacin, Linezolid, or Mupirocin against Staphylococcus aureus In Vitro

  2006cites this paper
• The Leptomycin Gene Cluster and Its Heterologous Expression in Streptomyces lividans

  2005cites this paper
• Rifampin-Resistant RNA Polymerase Mutants of Chlamydia trachomatis Remain Susceptible to the Ansamycin Rifalazil

  2005cites this paper
• Molekularbiologische Resistenzmechanismen und Therapieoptionen bei europäischen Staphylococcus aureus Isolaten

  2004cites this paper
• Development potential of rifalazil

  2003influential citation
• In Vitro Activities of Rifamycin Derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and Recent Clinical Isolates of Chlamydia pneumoniae

  2003cites this paper
• Antifungal and cancer cell growth inhibitory activities of 1‐(3′,4′,5′‐trimethoxyphenyl)‐2‐nitro‐ethylene

  2002cites this paper
• Méningite à pneumocoque et résistance bactérienne

  2002cites this paper
• Identification of enzymes responsible for rifalazil metabolism in human liver microsomes

  2000cites this paper
• Molecular Characterization of rpoBMutations Conferring Cross-Resistance to Rifamycins on Methicillin-Resistant Staphylococcus aureus

  1999cites this paper
• In Vitro Anti-Helicobacter pyloriActivities of New Rifamycin Derivatives, KRM-1648 and KRM-1657

  1999cites this paper
• Isolation and identification of major metabolites of rifalazil in mouse and human.

  1999cites this paper
• Management of Infections Due to Antibiotic-Resistant Streptococcus pneumoniae

  1998cites this paper
• HIV protease inhibitors, saquinavir, indinavir and ritonavir: inhibition of CYP3A4-mediated metabolism of testosterone and benzoxazinorifamycin, KRM-1648, in human liver microsomes.

  1997cites this paper
• Identification and antimicrobial activity of urinary metabolites of a rifamycin derivative in dog.

  1996cites this paper
• Anticytomegaloviral activity of methotrexate associated with preferential accumulation of drug by cytomegalovirus-infected cells

  1996cites this paper
• How effective is KRM-1648 in treatment of disseminated Mycobacterium avium complex infections in beige mice?

  1996cites this paper
• In vitro metabolism of a rifamycin derivative by animal and human liver microsomes, whole blood and expressed human CYP3A isoform.

  1996cites this paper
• Mechanism of action of antimycobacterial activity of the new benzoxazinorifamycin KRM-1648

  1995cites this paper
• Chapter 11. Antibacterial Agents

  1995cites this paper